Jakubikova, Jana <br/><br/>
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.  [electronic resource] 

 -  Blood  Apr 2011 
 - 4409-19 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-02-267344  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP-Binding Cassette Transporters--genetics<br/>Angiogenesis Inhibitors--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Bone Marrow Cells--cytology<br/>Cell Division--drug effects<br/>Cell Fractionation<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Colony-Forming Units Assay<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Lenalidomide<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--prevention & control<br/>Neoplastic Stem Cells--drug effects<br/>Signal Transduction--drug effects<br/>Stromal Cells--cytology<br/>Syndecan-1--metabolism<br/>Thalidomide--analogs & derivatives